Event > Conference >
SOT is returning to Salt Lake City for the first time in more than a decade for its 63rd Annual Meeting and ToxExpo. The 2024 meeting will feature five days of Featured and Scientific Sessions, poster presentations, and social events, as well as the popular three-day ToxExpo.
Will you be there too?
Head to our SOT 2024 exhibition stand – #507
Our dedicated team of creative problem solvers will be available to answer questions and share over a decade of organ-on-a-chip (OOC) expertise with you!
We look forward to meeting you at SOT 2024 to discuss how our PhysioMimix® range of products and services can help to improve the predictivity of your toxicology workflows and address your current workflow limitations – such as modeling the immune system in vitro and testing the safety of new modality drugs with human-specific modes of action.
Get familiar with our human-relevant single- and multi-organ in vitro models and learn more about their proven track record for delivering clinically translatable results, plus meet the newest product in our PhysioMimix OOC range of microphysiological systems – the PhysioMimix Single-organ HT System and associated Multi-chip Liver-48 plate.
More info coming soon…
Exhibitor Hosted Session
Early identification of DILI with in vitro human & animal liver microphysiological systems (MPS)
Identify drug-induced-liver-injury (DILI) and elucidate mechanisms of action using highly predictive human and preclinical animal liver MPS. Adopting MPS better informs in vivo study design, ensuring only the most promising candidate drugs are taken forward; animal use is decreased and the potential for adverse effects in the clinic is reduced.
Date: Tuesday, March 12 2023
Presentation from: Dr. Emily Richardson, CN Bio
Bridging the gap: human and preclinical animal microphysiological systems for assessing drug-induced liver injury during drug development
Due to their high relevance and predictivity, the human and animal Liver MPSs developed can be used in drug development pipelines to identify the hepatotoxicity of pharmaceutical compounds early, before proceeding into preclinical testing.
The Multi-chip Liver-48 plate facilitates the early determination of DILI concerns for multiple drug candidates, over wider concentration ranges and conditions/run. Used in conjunction with the PhysioMimix Single-organ HT System, this enhanced capacity enables the use of microphysiological systems within the lead optimization phase of drug discovery. Adoption enables better-informed insights into human DILI risk before in vivo studies so that only the most promising molecules proceed.
Utilize our Multi-chip Liver-12 plate to unlock the mechanisms of human DILI to reengineer, or inform the design of safer drugs in the future. Explore our animal Liver MPS to gain reassurance about the in vitro to in vivo translatability of MPS and their potential to better inform in vivo animal study design.
Date: Tuesday, March 12 2023
Room: Grand Ballroom J
Presentation from: Dr Ovidiu Novac, CN Bio
Our Team at SOT 2024
Dr Brooks joined CN Bio Innovations in 2022. He has over 25 years of experience in building businesses and leading high-performance research, product, marketing, and sales teams to develop and commercialize new biotechnology technologies globally for drug discovery, bioproduction and diagnostics.
Dr Brooks has held senior leadership positions in the USA and the UK, including Head of Business Operations and Managing Director of Horizon Discovery Ltd; Chief Commercial Officer and Executive Board member of Oxford Genetics Ltd; Head of Discovery Research Services at MilliporeSigma (Merck KGaA); and Global Marketing Manager at Sigma-Aldrich Corp. Dr Brooks has a BSc in Biochemistry from the University of Wales, a PhD in Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST), and an MBA from the University of Nottingham Business School.
Dr Kostrzewski has more than 15 years of experience in molecular and cellular biology research. He joined CN Bio in 2015 and was promoted to Director of Biology in 2018 with responsibility for biological model development and collaborative research projects with academia, pharma, and regulators. In 2021 he was promoted to VP of Science and Technology and then to Chief Scientific Officer in 2023, with responsibility for all technical activities, including developing new products, technologies, and assays, as well as contract research services. Dr Kostrzewski has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. He has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.
Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation, as well as at GlaxoSmithKline working in biopharmaceutical drug discovery and development. Dr Kostrzewski holds three degrees from the University of Sheffield and Imperial College London in Cell and Molecular Biology.
Dr Audrey Dubourg is CN Bio’s Product Manager for the PhysioMimix® OOC range of microphysiological systems. Prior to joining CN Bio, she worked as a postdoctoral scholar at the University of California – Los Angeles (UCLA), in the US, in the Microbiology, Immunology and Molecular Genetics department. She completed an MSc in microbiology at the University of Montpellier II, followed by a PhD in microbiology/parasitology at the University of East Anglia. Audrey has extensive experience in the disciplines of molecular biology and 3D mammalian cell culture. Since joining CN Bio, she has been actively involved in promoting the benefits of incorporating organ-on-a-chip technology into drug discovery and development workflows.
Joe Parisi is a Commercial Leader with 14 years’ experience in the life science sector. Joe joined CN Bio as the Americas Director of Sales in December 2023. He comes to CN Bio with valuable startup experience most recently at IsoPlexis and Purigen Biosystems, where he was responsible for building commercial opportunities across the US West. He was previously Sales Director at PhenomeX (now Bruker Cellular Analysis), where he managed the proteomics team in the US West focusing on capital equipment sales for single-cell functional analysis. Joe graduated from the University of Illinois Champaign-Urbana with a BSc in Molecular and Cellular Biology.
Dr Emily Richardson is a Lead Scientist in the R&D team at CN Bio. She joined the team in 2020 as a Senior Scientist and lead the development of the PhysioMimix lung and lung-liver MPS models. Emily is highly experienced in the application of complex cell biology to drug discovery, having previously worked in cellular therapeutics in an industry setting and as a trained biochemist with specialty in molecular biology. She completed her PhD at the University of Leicester, using 3D cell culture to determine molecular mechanisms driving highly metastatic lung cancers. She now leads R&D projects within the CN Bio team revolving around toxicology in the liver and the lung MPS, as well as driving collaborative projects with various academic, industry and regulatory partners.
Dr Ovidiu Novac is a Senior Scientist at CN Bio and a knowledgeable organ-on-a-chip (OOC) expert. Ovi performed as lead biological scientist in the NASH-in-a-Box project, is a knowledgeable organ-on-a-chip (OOC) expert, and has experience in assessing drug induced liver injury in vitro. Ovi has a background in the developmental stage of pharmaceutical and dermatological formulations and their performance assessment on human skin tissue ex vivo (topical and transdermal), and for strategic planning for further evaluation. During time spent in the pharma industry he contributed to delivering high quality results used for marketing purposes and in regulatory submissions. Ovi holds a BSc in biomaterials and prosthetic technologies and a PhD in chemistry and has been involved in research on controlled drug delivery systems since 2006.
Dr Scott Chilton is the Eastern US Sales Manager for CN Bio, based in Massachusetts, USA. Scott supports researchers who want to develop safe and effective therapeutics faster and more cost-effectively by adopting solutions that provide physiologically relevant and clinically translatable data. Scott holds a PhD from Harvard University and a BS from Massachusetts Institute of Technology.
Dr. Anthony Berger is CN-Bio’s US-based Field Application Scientist, providing support for the PhysioMimix® Organ-on-Chip benchtop platform. Anthony has an extensive research background in 3D cell culture, biomaterials, and microfluidics, focusing on how the microenvironment influences cellular decision-making. He is a proponent of complex 3D in vitro models and desires to decrease the barrier to entry of these technologies. Anthony received his BS from Indiana University (US), PhD from the University of Wisconsin (US), and completed a postdoctoral fellowship at Temple University (US).